Protease Inhibitors Drug Resistance Mutations in Turkish Patients with Chronic Hepatitis C

Basit Öğe Kaydı
dc.contributor.authorAltunok, Elif Sargin
dc.contributor.authorSayan, Murat
dc.contributor.authorAkhan, Sila
dc.contributor.authorAygen, Bilgehan
dc.contributor.authorYildiz, Orhan
dc.contributor.authorKoruk, Suda Tekin
dc.contributor.authorMistik, Resit
dc.date.accessioned2024-04-24T16:14:54Z
dc.date.available2024-04-24T16:14:54Z
dc.date.issued2016
dc.departmentDicle Üniversitesien_US
dc.description.abstractBackground: Drug resistance development is an expected problem during treatment with protease inhibitors (PIs), this is largely due to the fact that Pls are low-genetic barrier drugs. Resistance-associated variants (RAVs) however may also occur naturally, and prior to treatment with Pls, the clinical impact of this basal resistance remains unknown. In Turkey, there is yet to be an investigation into the hepatitis C (HCV) drug associated resistance to oral antivirals. Materials and methods: 178 antiviral-naive patients infected with HCV genotype 1 were selected from 27 clinical centers of various geographical regions in Turkey and included in the current study. The basal NS3 Pls resistance mutations of these patients were analyzed. Results: In 33 (18.5%) of the patients included in the study, at least one mutation pattern that can cause drug resistance was identified. The most frequently detected mutation pattern was T54S while R109K was the second most frequently detected. Following a more general examination of the patients studied, telaprevir (TVR) resistance in 27 patients (15.2%), boceprevir (BOC) resistance in 26 (14.6%) patients, simeprevir (SMV) resistance in 11 (6.2%) patients and faldaprevir resistance in 13 (7.3%) patients were detected. Our investigation also revealed that rebound developed in the presence of a Q80K mutation and amongst two V55A mutations following treatment with TVR, while no response to treatment was detected in a patient with a R55K mutation. Conclusion: We are of the opinion that drug resistance analyses can be beneficial and necessary in revealing which variants are responsible for pre-treatment natural resistance and which mutations are responsible for the viral breakthrough that may develop during the treatment. (C) 2016 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.en_US
dc.description.sponsorshipDepartment of Scientific Research Project of Kocaeli University; Turkish Society of Clinic Microbiology and Infectious Diseasesen_US
dc.description.sponsorshipThis study was funded by Department of Scientific Research Project of Kocaeli University and Turkish Society of Clinic Microbiology and Infectious Diseases.en_US
dc.identifier.doi10.1016/j.ijid.2016.07.003
dc.identifier.endpage5en_US
dc.identifier.issn1201-9712
dc.identifier.issn1878-3511
dc.identifier.pmid27401586
dc.identifier.scopus2-s2.0-84979254596
dc.identifier.scopusqualityQ1
dc.identifier.startpage1en_US
dc.identifier.urihttps://doi.org/10.1016/j.ijid.2016.07.003
dc.identifier.urihttps://hdl.handle.net/11468/15496
dc.identifier.volume50en_US
dc.identifier.wosWOS:000388326300001
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherElsevier Sci Ltden_US
dc.relation.ispartofInternational Journal of Infectious Diseases
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectBaseline Resistanceen_US
dc.subjectHepatitis C Virusen_US
dc.subjectMutationen_US
dc.subjectProtease Inhibitorsen_US
dc.titleProtease Inhibitors Drug Resistance Mutations in Turkish Patients with Chronic Hepatitis Cen_US
dc.titleProtease Inhibitors Drug Resistance Mutations in Turkish Patients with Chronic Hepatitis C
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu